期刊
ANNALS OF ONCOLOGY
卷 33, 期 5, 页码 466-487出版社
ELSEVIER
DOI: 10.1016/j.annonc.2022.02.003
关键词
consensus; lung cancer; treatment; testing; targeted therapy; EGFR
类别
The European Society for Medical Oncology (ESMO) conducted a virtual consensus-building process in 2021 to discuss the management of EGFR-mutant non-small-cell lung cancer. The experts developed recommendations on various topics, including tissue and biomarkers analyses, early and locally advanced disease, metastatic disease, clinical trial design, patient's perspective, and miscellaneous.
The European Society for Medical Oncology (ESMO) held a virtual consensus-building process on epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer in 2021. The consensus included a multidisciplinary panel of 34 leading experts in the management of lung cancer. The aim of the consensus was to develop recommendations on topics that are not covered in detail in the current ESMO Clinical Practice Guideline and where the available evidence is either limited or conflicting. The main topics identified for discussion were: (i) tissue and biomarkers analyses; (ii) early and locally advanced disease; (iii) metastatic disease and (iv) clinical trial design, patient's perspective and miscellaneous. The expert panel was divided into four working groups to address questions relating to one of the four topics outlined above. Relevant scientific literature was reviewed in advance. Recommendations were developed by the working groups and then presented to the entire panel for further discussion and amendment before voting. This manuscript presents the recommendations developed, including findings from the expert panel discussions, consensus recommendations and a summary of evidence supporting each recommendation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据